Value in health regional issues最新文献

{"title":"The Process of Listing Prostheses and Medical Devices in Thailand’s Universal Health Coverage","authors":"Manthana Laichapis PharmD ,&nbsp;Thanisa Thathong PharmD ,&nbsp;Supisara Kanjanaphrut PharmD ,&nbsp;Sirada Thansuwanwong PharmD ,&nbsp;Yotsaya Kunlamas PharmD ,&nbsp;Puree Anantachoti PhD ,&nbsp;Bunchai Chongmelaxme PhD","doi":"10.1016/j.vhri.2024.100990","DOIUrl":"https://doi.org/10.1016/j.vhri.2024.100990","url":null,"abstract":"<div><h3>Objectives</h3><p>This study aimed to characterize the processes of listing prostheses and medical devices in all insurance schemes.</p></div><div><h3>Methods</h3><p>A literature review was performed, and in-depth interviews were conducted with the representatives of 6 insurance agencies. Civil Servant Medical Benefits Scheme (CSMBS), Social Security Scheme, Local Government Officer Scheme (LGOS), State Enterprise Scheme (SES), Universal Coverage Scheme (UCS), and Non-Thai Resident Scheme (NTRS).</p></div><div><h3>Results</h3><p>The outcomes of interest were structure details and the body of the working groups, listing processes, and key assessment criteria. Each insurance scheme’s process can be summarized in 5 steps: (1) receiving the proposed topics of health technologies, (2) screening, (3) selection, (4) consideration, and (5) approval and publicization. Notably, the organizational structures and working group compositions vary across schemes, leading to differences in process activities and assessment criteria. LGOS and SES are exceptions because they follow the application process of CSMBS. UCS demonstrates the most transparent process, providing specific working groups that are competent in undertaking each activity. The processes of listing prostheses and medical devices vary across health insurance in Thailand, leading to varying numbers of health technologies covered by insurance schemes.</p></div><div><h3>Conclusions</h3><p>This study characterizes prostheses and medical device listing processes in 6 Thai Universal Health Coverage insurance schemes (CSMBS, Social Security Scheme, UCS, LGOS, SES, and Non-Thai Resident Scheme). Variations in processes result in differing technology listings. It offers essential insights for healthcare professionals and policy makers.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"42 ","pages":"Article 100990"},"PeriodicalIF":2.0,"publicationDate":"2024-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141083347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of COVID-19 on Healthcare Utilization in Turkey","authors":"Zeynep B. Uğur PhD ,&nbsp;Ayşenur Durak MSc","doi":"10.1016/j.vhri.2024.101000","DOIUrl":"https://doi.org/10.1016/j.vhri.2024.101000","url":null,"abstract":"<div><h3>Objectives</h3><p>This study investigates the impact of the COVID-19 pandemic on healthcare utilization in Turkey.</p></div><div><h3>Methods</h3><p>We utilized individual-level data derived from Turkish Statistical Institute’s annual surveys between 2014 and 2022 and estimated probit regression models.</p></div><div><h3>Results</h3><p>We find that COVID-19 pandemic reduced healthcare utilization by 11.8% after taking into account a large set of background variables. Although our study finds that the elderly and those with health problems are more likely to use healthcare services under normal circumstances, the COVID-19 pandemic has caused notable drops in the healthcare utilization among the elderly (−6.5%) and those with health problems (−3.8%). Although those without health insurance had lower utilization of healthcare services before the pandemic, during the pandemic they were not particularly hit.</p></div><div><h3>Conclusion</h3><p>We conclude that the pandemic did not lower the healthcare utilization in Turkey because of the supply constraints. Also, the evidence points to the reduced demand due to the fear of contagion rather than financial concerns.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"43 ","pages":"Article 101000"},"PeriodicalIF":2.0,"publicationDate":"2024-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140947918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mortalidad, Secuelas Clínicas y Calidad de Vida Luego del Alta de Unidades de Cuidados Intensivos en Pacientes con COVID-19: Estudio Multicéntrico Descriptivo en Argentina","authors":"Fernando Argento Ms(c) ,&nbsp;Manuel Donato Ms(c) ,&nbsp;Dario Villalba Spec ,&nbsp;Marisol García Sarubbio Spec ,&nbsp;Anabella Giménez PT ,&nbsp;Agustin Ciapponi PhD ,&nbsp;Federico Augustovski PhD","doi":"10.1016/j.vhri.2024.100989","DOIUrl":"https://doi.org/10.1016/j.vhri.2024.100989","url":null,"abstract":"<div><h3>Objective</h3><p>Patients with COVID-19 who require hospitalization in an intensive care unit, in addition to being at risk of presenting premature death, have higher rates of complications. This study aimed to describe mortality, rehospitalizations, quality of life, and symptoms related to postintensive care syndrome (PICS) and prolonged COVID-19 in patients with COVID-19 discharged from the intensive care unit in hospitals in Argentina.</p></div><div><h3>Methods</h3><p>A cross-sectional study was conducted in 4 centers in the Autonomous City and province of Buenos Aires as of December 2022. The variables of interest were mortality after discharge, rehospitalization, health-related quality of life, post-COVID-19–related symptoms, cognitive status, and PICS. Data collection was by telephone interview between 6 and 18 months after discharge.</p></div><div><h3>Results</h3><p>A total of 124 patients/families were contacted. Mortality was 7.3% (95% CI: 3.87-13.22) at 14.46 months of follow-up after discharge. Patients reported a reduction of the EQ-5D-3L visual analog scale of 13.8 points, reaching a mean of 78.05 (95% CI: 73.7-82.4) at the time of the interview. Notably, 54.4% of patients (95% CI: 41.5-66.6) reported cognitive impairment and 66.7% (95% CI: 53.7-77.5) developed PICS, whereas 37.5% (95% CI: 26-50.9) had no symptoms of prolonged COVID-19.</p></div><div><h3>Conclusion</h3><p>The results showed a significant impact on the outcomes studied, consistent with international evidence.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"42 ","pages":"Article 100989"},"PeriodicalIF":2.0,"publicationDate":"2024-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140901711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-Effectiveness of Ibrutinib for Chronic Lymphocytic Leukemia Treatment in India: Is Evidence Really at Crossroads?","authors":"Gaurav Jyani PhD ,&nbsp;Nidhi Gupta MD","doi":"10.1016/j.vhri.2024.100991","DOIUrl":"https://doi.org/10.1016/j.vhri.2024.100991","url":null,"abstract":"<div><p>In recent years, newer drugs, such as ibrutinib, have shown promising improvements in the survival of patients with chronic lymphocytic leukemia (CLL). Despite their effectiveness, concerns about their cost have arisen, prompting the need for an evaluation of their cost-effectiveness. However, recent assessments of ibrutinib’s cost-effectiveness for treating CLL in India reveal divergent conclusions. The discord centers on divergent cost-effectiveness thresholds, comparator regimens, cost calculations, and outcome valuation approaches. Such discrepancies affect public health decisions and patient care. The recommendation calls for adherence to methodological guidelines by future studies, fostering consistent findings to empower policy makers and clinicians in leveraging economic evidence for informed decision making in CLL treatment strategies.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"42 ","pages":"Article 100991"},"PeriodicalIF":2.0,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140879217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of Life in Transfusion-Dependent Thalassemia Patients in Greece Before and During the COVID-19 Pandemic","authors":"Philippos Klonizakis PhD ,&nbsp;Robert J. Klaassen PhD ,&nbsp;Noémi Roy PhD ,&nbsp;Ioanna Papatsouma PhD ,&nbsp;Maria Mainou MSc ,&nbsp;Ioanna Christodoulou BHSc ,&nbsp;Apostolos Tsapas PhD ,&nbsp;Efthymia Vlachaki PhD","doi":"10.1016/j.vhri.2024.100986","DOIUrl":"https://doi.org/10.1016/j.vhri.2024.100986","url":null,"abstract":"<div><h3>Objectives</h3><p>The peak of the COVID-19 pandemic was a challenging situation for transfusion-dependent thalassemia (TDT) patients. The objectives of this study were to measure the quality of life (QoL) in TDT patients during the COVID-19 lockdown restriction measures, compare the results with the pre-COVID-19 era, and evaluate the influence of sociodemographic and clinical factors on QoL.</p></div><div><h3>Methods</h3><p>This was a cross-sectional study of 110 consecutively selected adult TDT patients, during the stringent lockdown restriction measures implemented in Greece. All participants completed a combination of 2 QoL questionnaires, the generic Short-Form Health Survey 36 version 2 and the disease-specific Transfusion-Quality of life (TranQol). We used the “1/2 SD method,” a distribution-based approach to calculate minimal clinically important differences and clinically compare the QoL scores between the pre-COVID-19 and post-COVID-19 era. A backward stepwise linear regression was selected to explore the influence of potential predictors on TranQol scores.</p></div><div><h3>Results</h3><p>The Short-Form Health Survey 36 version 2 and TranQol scores remained low but not clinically different compared with the pre-COVID-19 era. Older, married, and higher educated TDT patients exhibited significantly lower TranQol summary scores. The patients who reported a negative effect of the COVID-19 pandemic had significantly lower TranQol scores in summary and all subdomains except for school and career.</p></div><div><h3>Conclusions</h3><p>During the COVID-19 pandemic, the overall QoL of TDT patients was clinically similar to the status of the pre-COVID-19 era. Nevertheless, most of the significant QoL subdomains were negatively affected, and distinct groups of TDT patients were more vulnerable.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"42 ","pages":"Article 100986"},"PeriodicalIF":2.0,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140893443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lenalidomide or Thalidomide for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma? An Overview of Systematic Reviews","authors":"Marília Berlofa Visacri PhD ,&nbsp;Mayra Carvalho Ribeiro MSc ,&nbsp;Denis Satoshi Komoda ,&nbsp;Bruno Kosa Lino Duarte PhD ,&nbsp;Carlos Roberto Silveira Correa PhD ,&nbsp;Flávia de Oliveira Motta Maia PhD ,&nbsp;Daniela Fernanda dos Santos Alves PhD","doi":"10.1016/j.vhri.2024.100998","DOIUrl":"https://doi.org/10.1016/j.vhri.2024.100998","url":null,"abstract":"<div><h3>Objectives</h3><p>To present an overview of evidence of efficacy, safety, and health-related quality of life of lenalidomide or thalidomide for transplant-ineligible multiple myeloma.</p></div><div><h3>Methods</h3><p>A literature search was performed in 5 databases until July 2022. We included systematic reviews with network meta-analyses of randomized controlled trials on the use of lenalidomide compared with thalidomide for transplant-ineligible multiple myeloma. The A Measurement Tool to Assess Systematic Reviews 2 was used to appraise the quality of included reviews. The results were focused on the lenalidomide + dexamethasone until disease progression (RDc) versus thalidomide + dexamethasone until disease progression (TDc) and induction with melphalan + prednisone + lenalidomide, followed by maintenance with lenalidomide (MPR-R) versus induction with melphalan + prednisone + thalidomide, followed by maintenance with thalidomide (MPT-T) regimens.</p></div><div><h3>Results</h3><p>Nine studies were included. Only 1 study did not show any weakness in critical domains of A Measurement Tool to Assess Systematic Reviews 2. For overall survival, RDc proved to be superior to TDc; however, no study showed significant difference between MPR-R and MPT-T. For progression-free survival, 2 of 3 studies showed that RDc is better than TDc; however, no difference between MPR-R and MPT-T was found. Regarding safety, these lenalidomide-based regimens had a lower risk for neurologic adverse events, with an increased risk of hematologic adverse events. No health-related quality of life meta-analyses were found.</p></div><div><h3>Conclusions</h3><p>These findings suggest that, in terms of efficacy and safety, lenalidomide-based regimen is a good option for treatment of transplant-ineligible multiple myeloma in the public health system of Brazil, especially for those patients who develop severe neuropathy with thalidomide.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"43 ","pages":"Article 100998"},"PeriodicalIF":2.0,"publicationDate":"2024-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140880280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microcosting Analysis of Advanced Ovarian Cancer: Real-World Evidence From the Perspective of a Reference Public Brazilian Hospital","authors":"Carolina Martins BPharm ,&nbsp;Raquelaine Padilha BSN, MSc ,&nbsp;Lucas Okumura BPharm, MSc ,&nbsp;Andreia Melo MD, MSc, PhD ,&nbsp;Rodrigo Costa BPharm, PhD","doi":"10.1016/j.vhri.2024.100999","DOIUrl":"https://doi.org/10.1016/j.vhri.2024.100999","url":null,"abstract":"<div><h3>Objectives</h3><p>Evaluate the cost of advanced ovarian cancer, using the microcosting technique, based on real-world evidence from the perspective of a reference Brazilian public hospital.</p></div><div><h3>Methods</h3><p>Retrospective cohort study of patients newly diagnosed with advanced ovarian cancer in 2017 and followed-up for up to 5 years. A bottom-up microcosting method was applied, using the activity-based cost approach, which evaluates service costs based on activity consumption throughout patients’ journey.</p></div><div><h3>Results</h3><p>The results indicate a median overall survival of 35.3 months and a median age of 57 years (33-80 years old). The average cost per patient was USD 34 991.595 over a period of 35.3 months, with admissions because of the disease progression and end-of-life care being the most relevant.</p></div><div><h3>Conclusions</h3><p>The results show that the costs of activities currently involved in the treatment of advanced ovarian cancer represent an important economic impact for the public health system. These data can support future analyses on the impact of incorporating new technologies for the treatment of ovarian cancer and on the financing and sustainability of the Brazilian public healthcare system.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"43 ","pages":"Article 100999"},"PeriodicalIF":2.0,"publicationDate":"2024-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140843177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incremental Healthcare Costs of Diabetes Mellitus in a Middle-Income Country Using Administrative Healthcare Data","authors":"Santiago Castro-Villarreal MSc ,&nbsp;Sara Miksi MSc ,&nbsp;Adriana Beltrán-Ostos MD, MSc ,&nbsp;Carlos F. Valencia MSc, PhD","doi":"10.1016/j.vhri.2024.100992","DOIUrl":"https://doi.org/10.1016/j.vhri.2024.100992","url":null,"abstract":"<div><h3>Objectives</h3><p>To estimate the incremental medical cost of diabetes mellitus using information from administrative databases in Colombia.</p></div><div><h3>Methods</h3><p>We carried out a retrospective cohort study with administrative health databases from Colombian population affiliated in the contributory health insurance scheme. We used an operative definition to select the cohort with diabetes. Incremental cost and cost ratio of diabetes were estimated using an inverse probability weighting of treatment approach to find the causal effect of having the disease. Weights were calculated by a propensity score method using a Random Forest model. The flexibility of this machine learning algorithm allows to have a better specification and bias reduction. Additionally, we reported incremental costs and cost ratios with confidence intervals using bootstrapping and analyzed costs by age groups and complications associated with diabetes.</p></div><div><h3>Results</h3><p>The estimated prevalence of diabetes was 2834 per 100 000 cases, in 2018. The group with diabetes was comprised 634 015 people and the control group 1 524 808. The calculated annual direct medical cost was $860, for which the incremental cost was $493 and the cost ratio 2.34. The incremental annual cost for some type of complication ranges from $1239 to $2043, renal complication being the most expensive. Incremental cost by age groups ranges from $347 to $878, being higher in younger people.</p></div><div><h3>Conclusions</h3><p>Although the cost of diabetes in Colombia ranges among the global averages and is similar to other Latin-American countries, a greater incremental cost was found in patients with renal, circulatory, and neurologic complications.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"43 ","pages":"Article 100992"},"PeriodicalIF":2.0,"publicationDate":"2024-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2212109924000256/pdfft?md5=0f1b0c4f6ecc7851bc484bc6dd03faa6&pid=1-s2.0-S2212109924000256-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140843180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Strategic Approaches to Reducing the Burden of Atopic Dermatitis in the Middle East and Africa Region","authors":"Baher Elezbawy MPH ,&nbsp;Mohamed Farghaly PhD ,&nbsp;Atlal Al Lafi PhD ,&nbsp;Mary Gamal MSc ,&nbsp;Mirna Metni PharmD ,&nbsp;Willem Visser PhD ,&nbsp;Hana Al-Abdulkarim MSc ,&nbsp;Meriem Hedibel PharmD ,&nbsp;Ahmad Nader Fasseeh PhD ,&nbsp;Sherif Abaza MBA ,&nbsp;Zoltán Kaló PhD","doi":"10.1016/j.vhri.2024.100987","DOIUrl":"https://doi.org/10.1016/j.vhri.2024.100987","url":null,"abstract":"<div><h3>Objectives</h3><p>Atopic dermatitis (AD) creates a significant burden on patients and society. This study proposes a set of health policy interventions that can reduce the burden of AD in the Middle East and Africa.</p></div><div><h3>Methods</h3><p>We conducted a scoping review to find relevant actions that have been implemented or recommended to decrease AD burden globally. An expert panel was conducted to discuss the review findings, then experts were surveyed to suggest the most efficient actions. Finally, survey results and recommendations were formulated into key actions to reduce the burden in the Middle East and Africa region.</p></div><div><h3>Results</h3><p>Recommended actions were related to 5 domains; capacity building, guidelines, research, public awareness, and patient support and education. Several actions related to each domain can help reduce the burden. One of the most advocated recommendations was investing in patient education through trained healthcare professionals. Understanding the disease and learning how to control it is a key cornerstone to treatment optimization and reducing the burden. Multidisciplinary care, publishing defined therapeutic guidelines, and investing in research were the most recommended actions based on the experts’ discussion and survey results.</p></div><div><h3>Conclusions</h3><p>Although the burden of AD is the highest among dermatological diseases, a well-grounded action plan has the potential to reduce the disease burden. Decision makers may develop a national AD action plan by selecting the most relevant items of this study based on their potential impact, feasibility, timeliness, and affordability.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"42 ","pages":"Article 100987"},"PeriodicalIF":2.0,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2212109924000207/pdfft?md5=d82774353281599164997d00f05769ee&pid=1-s2.0-S2212109924000207-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140823266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Partial-Cost Analysis and Economic Impact of Ambulatory Coronary Angioplasty in a Private Hospital in the Caribbean","authors":"Licurgo J. Cruz MD ,&nbsp;Helio M. Grullón-Rodríguez MD ,&nbsp;Yanely López-Bencosme MD ,&nbsp;Sergio Gresse Jr. MPH ,&nbsp;Yinny Cen Feng MD ,&nbsp;Anthony Gutiérrez-Martínez MD, MSc","doi":"10.1016/j.vhri.2024.100988","DOIUrl":"https://doi.org/10.1016/j.vhri.2024.100988","url":null,"abstract":"<div><h3>Objectives</h3><p>This study aimed to assess direct costs of percutaneous coronary intervention (PCI) without hospital admission versus PCI with hospital admission longer than 24 hours in a private hospital-institutional perspective in the Dominican Republic in 2022.</p></div><div><h3>Methods</h3><p>This study has a comparative approach based on a prospective cross-sectional partial-cost analysis. We evaluated the direct costs of 10 patients from PCI without hospital admission approach and 10 patients from a hospital admission longer than 24 hours as a control group. We used a “first-come-first-served” approach from December 2021 to March 2022. The analysis used the electronic invoice generated for each patient.</p></div><div><h3>Results</h3><p>PCI without hospital admission approach represents $472.56 in patient savings, equivalent to a cost reduction of 12.5%. The subcosts analysis showed the pharmacy section as the main driver of the overall cost difference.</p></div><div><h3>Conclusions</h3><p>PCI without hospital admission was economically cost-saving compared with the control approach in direct costs in the Dominican perspective. The economic benefit is substantial and compliments the ease of use. This analysis may lead to improvements in institutional management of resources and can potentially be adapted to other health systems in the region.</p></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"42 ","pages":"Article 100988"},"PeriodicalIF":2.0,"publicationDate":"2024-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140825256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}